Simplifying spectra with middle-down characterization of antibodies and ADCs

Wednesday, October 29, at 16:00 GMT | 17:00 CET | 12:00 EDT | 9:00 PDT

Monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) are pivotal in disease treatment. These innovative therapies have revolutionized the way we approach complex diseases, offering targeted and effective treatment options.

Join our expert speakers as they delve into the intricacies of how middle-down mass spectrometry (MD MS) with proton transfer charge reduction (PTCR) simplifies spectra for precise analysis, making it easier for scientists to obtain accurate and reliable data.

Plus, discover how the Thermo Scientific^™ Orbitrap^™ Ascend Tribrid^™ Biopharma mass spectrometer and PTCR enhance mAb and ADC characterization for better biotherapeutic development. Key benefits include improved accuracy, fewer false positives, and efficient characterization.

Key learning objectives:

• Learn new approaches to accurately characterize the drug-to-antibody ratio (DAR), drug load distribution, and the exact sites of conjugation of ADCs
• Discover how PTCR can be leveraged to further enhance drug characterization using middle-down mass spectrometry (MD MS)
• Understand how to safely and accurately accelerate your drug to market

Who should attend?

Researchers, scientists, and regulatory professionals specifically working with monoclonal antibodies and antibody-drug conjugates.

Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.